mocravimod
Phase 3Small molecule
mocravimod is one of 9 small molecule programs targeting Adult Acute Myeloid Leukemia. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
13 competitors in Adult Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Cytosar
TevaApproved
Revuforj
SSyndax Pharmaceuticals
Approved
Standard Dose ARA-C
NNational Research Center for Hematology, Russia
Approved
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
High Dose Ara-C
PProf. Dr. M. Dreyling (co-chairman)
Approved
Ara-C
KKaryopharm Therapeutics Inc
Phase 2
mocravimod
PPriothera SAS
Phase 3
Venclexta
AbbViePreclinical
Cerubidine
HHikma Pharmaceuticals LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Adult Acute Myeloid Leukemia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for mocravimod. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- PPriothera SAS